Day One Biopharmaceuticals Inc
NASDAQ:DAWN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
12.03
17.69
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Day One Biopharmaceuticals Inc
Additional Paid In Capital
Day One Biopharmaceuticals Inc
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
Day One Biopharmaceuticals Inc
NASDAQ:DAWN
|
Additional Paid In Capital
$805.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Additional Paid In Capital
$21.2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
18%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Additional Paid In Capital
$6.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
2%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Additional Paid In Capital
$12.7B
|
CAGR 3-Years
17%
|
CAGR 5-Years
24%
|
CAGR 10-Years
18%
|
|
Day One Biopharmaceuticals Inc
Glance View
Day One Biopharmaceuticals Inc. emerged on the healthcare scene with a mission deeply rooted in a poignant reality: the need for tailored cancer treatments for children. Named symbolically to reflect the fresh start they aspire to offer to young patients, Day One focuses on developing and commercializing targeted therapies specifically for pediatric cancer, a field historically overlooked by the larger pharmaceutical industry. The company employs innovative drug development strategies, utilizing molecular targeted therapy—a precise approach that zeroes in on cancer cells while sparing healthy ones. This methodology not only underscores their commitment to efficacy and safety but also positions them as pioneers in an area rife with unmet medical needs. Fundamentally, the company generates its revenue through the successful commercialization of its therapies. It channels resources into robust clinical trials to demonstrate the efficacy and safety of its drugs, seeking regulatory approvals as key milestones. Licensing deals also play a crucial role in its business model, as partnerships with larger pharmaceutical firms enable Day One to expand its reach and scale. This strategic blending of in-house development and external alliances allows Day One to navigate the complex biopharmaceutical landscape efficiently, driving both innovation and financial sustainability. As they continue to advance their pipeline, the company aims to reshape pediatric oncology, demonstrating that profitable ventures can indeed be built around noble societal missions.
See Also
What is Day One Biopharmaceuticals Inc's Additional Paid In Capital?
Additional Paid In Capital
805.1m
USD
Based on the financial report for Dec 31, 2023, Day One Biopharmaceuticals Inc's Additional Paid In Capital amounts to 805.1m USD.
What is Day One Biopharmaceuticals Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 1Y
34%
Over the last year, the Additional Paid In Capital growth was 34%.
You don't have any saved screeners yet
